# Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation

> **NCT01051388** · PHASE3 · COMPLETED · sponsor: **Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan** · enrollment: 280 (actual)

## Conditions studied

- Cardio-cerebrovascular Disease

## Interventions

- **DRUG:** Low-dose PPI (Rabeprazole sodium)
- **DRUG:** High-dose PPI (Rabeprazole sodium)
- **DRUG:** Non-PPI (Gefarnate)

## Key facts

- **NCT ID:** NCT01051388
- **Lead sponsor:** Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-07
- **Final completion:** 2010-12
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2011-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051388, "Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01051388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*